library.onepin.app/wolverine-blend Peptide Education Library
Education only, not medical advice 21+ Every dose is an example to finalize with a licensed provider

OnePin Peptide Library · Repair & Recovery

Repair & Recovery Pre-mixed repair blend Not FDA-approved · investigational

Wolverine Blend

Wolverine Stack

Pre-mixed repair blendBPC-157 + TB-500 combinationTissue repair and recoveryAnti-inflammatory

The Wolverine Blend is the most widely used pre-mixed repair peptide combination, pairing BPC-157 and TB-500 in a single vial. Named for its regenerative parallels, this blend combines two peptides with complementary but non-overlapping repair mechanisms: BPC-157 drives local tissue repair through angiogenesis and nitric oxide modulation, while TB-500 promotes systemic repair through actin polymerization and cell migration. Together they cover the full healing cascade from inflammation reduction to structural remodeling.

Quick Start
Route
Subcutaneous (SubQ) injection near injury site or abdomen
Start low
250mcg BPC + 250mcg TB per injection
Frequency
Daily
Timing
No fasting required

Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.

Tiered Protocols · lowest first
Quick Start
Conservative start
250mcg BPC + 250mcg TB per injection · Subcutaneous (SubQ) injection near injury site or abdomen · Daily
Lowest starting point. Hold about a week to assess tolerance before stepping up.
250mcg BPC + 250mcg TB per injection
Daily
Intermediate
Ultimate Tissue Recovery
500-1000 mcg total · SubQ · Daily
anecdotal · community
500-1000 mcg total
Daily
Reconstitution CalculatorU-100
050100u
Draw to
units
01

How it works

The Wolverine Blend combines two complementary repair mechanisms that together address the full tissue healing cascade:

The Wolverine Blend combines two complementary repair mechanisms that together address the full tissue healing cascade:

BPC-157 Component: Activates local repair pathways by upregulating VEGF (vascular endothelial growth factor) for new blood vessel formation at injury sites, modulating the nitric oxide system for improved blood flow and cellular signaling, increasing GH receptor expression to amplify growth hormone effects on target tissue, and activating the FAK-paxillin pathway to drive cell migration to damaged areas. BPC-157 also promotes organized collagen deposition over scar tissue formation.

TB-500 Component: Drives systemic repair through regulation of actin polymerization and cytoskeletal dynamics. By controlling the balance between G-actin monomers and F-actin filaments, TB-500 enables repair cells (fibroblasts, endothelial cells, stem cells) to migrate effectively to injury sites throughout the body. TB-500 also suppresses NF-kB inflammatory signaling and promotes angiogenesis through distinct pathways from BPC-157.

Synergy: BPC-157's local angiogenesis and NO modulation create the vascular infrastructure, while TB-500's actin-driven cell migration delivers repair cells through that infrastructure. BPC-157's GH receptor upregulation amplifies the effects of both endogenous GH and any GH-releasing peptides used concurrently. The combination consistently outperforms either peptide used alone in anecdotal reports.

02

What to expect

Early
Days 1–7

Days 1-7: Reduced inflammation and pain from both BPC-157 (local NO modulation) and TB-500 (NF-kB suppression). Acute injuries may show noticeable improvement within 48-72 hours. Mild warmth or redness at injection site is normal and resolves in minutes.

Mid
Weeks 2–4

Weeks 2-4: Significant healing progress. BPC-157 angiogenesis creating new blood vessel networks at injury sites while TB-500 cell migration delivers repair cells. Chronic injuries begin responding. Tendon and ligament pain markedly reduced. This is the period of most dramatic improvement for most users.

Later
Weeks 4–12

Weeks 4-12: Structural repair consolidation. Collagen remodeling from BPC-157 continues. TB-500 anti-fibrotic effects reduce scar tissue formation. Chronic issues that developed over months may need this full timeframe. Consider cycling off after 8-12 weeks with a 4-week break.

03

Evidence

HumanModerate
AnimalStrong
In-vitroPresent
2011The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration · Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH, Journal of Applied Physiology ↗peer reviewed
2006Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation · Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P, Journal of Orthopaedic Research ↗peer reviewed
2010Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat · Cerovecki T, Bojanic I, Brcic L, et al, Journal of Orthopaedic Research ↗peer reviewed
2021Stable Gastric Pentadecapeptide BPC 157 and Wound Healing · Seiwerth S, Sever M, Sikiric P, et al, Frontiers in Pharmacology ↗review
04

The honest take

Wolverine-like regeneration of damaged tissue

Marketing hyperbole. Both peptides accelerate normal healing processes but do not enable regeneration of lost tissue. Animal data shows faster repair, not regrowth of structures.

BPC-157 and TB-500 are synergistic and work better together than alone
Plausible

Mechanistically plausible - they target different repair pathways (angiogenesis vs cell migration). However, no controlled human or animal study has directly compared the combination to either peptide alone.

BPC-157 has no known lethal dose (LD50)

Supported by toxicology data. Multiple animal studies have failed to establish an LD50, indicating a very wide safety margin. This does not guarantee safety at all doses in humans.

05

Interactions & stacking

What's safe to combine, and what belongs in a separate pin.

Safe & synergistic

AOD-9604No interaction. Different mechanisms (fat metabolism vs tissue repair). Safe in same syringe.
MOTS-cMitochondrial peptide with different pathway. Safe in same syringe.
SelankNo reactive residue conflicts. Safe in same syringe.
SemaxNo reactive residue conflicts. Safe in same syringe.

Keep separate

LL-37BPC-157 is anionic. LL-37 is cationic (+6 charge). Charge interaction on contact causes aggregation.
CJC-1295 with DACDAC maleimide linker may react with peptides in syringe. Pin CJC-DAC separately.
NAD+Acidic pH of NAD+ can denature BPC-157. Different routes anyway (NAD+ is typically IM).
GlutathioneThiol chemistry may interfere. Pin separately (Glutathione is typically IM).
06

Side effects & safety

Commonly reported

  • Mild injection site redness or warmth (resolves in minutes)
  • Occasional lightheadedness immediately post-injection
  • Temporary GI changes during gut healing phase
  • Mild fatigue in first few days as repair processes activate

Less common & notes

  • Rarely reported: headache, transient nausea, increased dream vividness.
  • Both BPC-157 and TB-500 have exceptionally favorable safety profiles in animal studies.
  • BPC-157 has no established LD50 (no lethal dose found).
  • However, long-term human safety data for the combination does not exist.
07

Pharmacokinetics

Illustrative plasma concentration · 24 h
Half-life
BPC-157: ~2 min (rapid distribution); TB-500: ~2-3 hours (systemic)
Peak · Tmax
BPC-157: minutes (local effects); TB-500: 1-2 hours
Elimination
BPC-157: ~20 hours (activity); TB-500: ~12-16 hours
Activity
BPC-157: 12-24 hours (VEGF/eNOS modulation persists beyond plasma clearance); TB-500: 24-48 hours (actin effects persist due to longer half-life)

Storage. Reconstitute with bacteriostatic water. Store refrigerated at 2-8 degrees C. Both BPC-157 and TB-500 are reasonably stable peptides. Shelf life approximately 28 days after reconstitution. Do not freeze after reconstitution. Protect from prolonged light exposure. Discard if cloudy or particulate matter visible.

08

Regulatory status

Not FDA-approved. Available through compounding pharmacies with prescription in some jurisdictions and through research chemical suppliers. Both BPC-157 and TB-500 are classified as research peptides. BPC-157 has been granted FDA Orphan Drug Designation for short bowel syndrome. All current human use of this blend is experimental and off-label.

Put it to work

Calculate, log & track

Open Wolverine Blend straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.

Open Wolverine Blend in the app →

Go deeper

The guide & community

The complete Wolverine Blend walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.

Join the community ↗
Open in app Community